Management of Asymptomatic Atrial Fibrillation

Evaluation of Thromboembolic Risk

The European Society of Cardiology recommends using the CHA₂DS₂-VA score to assess thromboembolic risk in all patients with asymptomatic atrial fibrillation 1, 3
Oral anticoagulation is recommended for all patients with a CHA₂DS₂-VA score ≥2 to prevent stroke and thromboembolic events, as per the European Heart Journal guidelines 1, 4
For patients with a CHA₂DS₂-VA score of 0 (men) or 1 (women), it is reasonable to omit antithrombotic treatment, according to the American College of Cardiology 3

The European Heart Journal recommends that direct oral anticoagulants (DOACs) such as apixaban, dabigatran, edoxaban, or rivaroxaban are preferred over vitamin K antagonists (VKAs) like warfarin due to a lower risk of intracranial hemorrhage 1, 3
For patients on warfarine, the target INR should be maintained between 2.0 and 3.0 with weekly monitoring during initiation and monthly when stable, as per the American College of Cardiology guidelines 3
A reduced dose of DOAC is not recommended unless patients meet specific dose-reduction criteria to avoid underdosing and preventable thromboembolic events, according to the European Heart Journal 1, 4

For asymptomatic patients, a heart rate control strategy is recommended as the initial approach, as suggested by the European Society of Cardiology 2, 5
For patients with left ventricular ejection fraction (LVEF) >40%, beta-blockers, diltiazem, verapamil, or digoxin are recommended as first-line medications, according to the American College of Cardiology 2, 4

Effective management of comorbidities and risk factors is essential to prevent the progression of atrial fibrillation, as recommended by the European Heart Journal 1
Tight glycemic control is recommended for individuals with diabetes and atrial fibrillation, according to the European Society of Cardiology 1
Sodium-glucose cotransporter 2 inhibitors are recommended for patients with heart failure and atrial fibrillation, regardless of left ventricular ejection fraction, as per the European Heart Journal guidelines 1

Anticoagulation should be continued according to the patient's stroke risk, even after restoration of sinus rhythm, as recommended by the American College of Cardiology 2, 4
Bleeding risk scores should not be used to decide whether to start or stop anticoagulation but rather to identify and manage modifiable bleeding risk factors, according to the European Society of Cardiology 2, 4
Underdosing of DOACs increases the risk of preventable thromboembolic events, as warned by the European Heart Journal 1